Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Incyte Corporation    INCY   US45337C1027

INCYTE CORPORATION (INCY)

28
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on INCYTE CORPORATION
01:47a INCYTE : to Collect $25 Million Milestone Payment from Novartis
01/28 INCYTE : Announces Publication of Phase III RESPONSE Trial in Patients with Poly..
01/27 INCYTE : to Report Fourth Quarter/Year-End 2014 Financial Results on February 12
01/26 INCYTE : Change in Directors or Principal Officers (form 8-K)
01/23 UNILIFE : Appoints David Hastings as Chief Financial Officer
01/23 INCYTE : and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology An..
01/23 INCYTE : Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Ap..
01/21 INCYTE : Diagnostics Selects Don Larsen as New CEO
01/20 INCYTE : Diagnostics Selects Don Larsen as New CEO
01/18 INCYTE : Board Adds 2 New Directors
01/14 INCYTE : Board Names 2 New Directors
01/13 UNILIFE : Appoints David Hastings as Chief Financial Officer
01/13 UNILIFE : David Hastings named new chief financial officer at Unilife
01/13 UNILIFE : Appoints David Hastings as Chief Financial Officer
01/12 INCYTE : Entry into a Material Definitive Agreement, Financial Statements and Ex..
01/09 INCYTE : Change in Directors or Principal Officers (form 8-K)
01/09 INCYTE : Board Appoints Two New Directors
01/01 INCYTE : to Present at the 33rd Annual J. P. Morgan Healthcare Conference
2014 INCYTE : to Present at the 33rd Annual J. P. Morgan Healthcare Conference
2014 INCYTE : Gets FDA Approval for Jakafi (ruxolitinib)
2014 ELI LILLY : Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Tri..
2014 INCYTE : 'Nashville' Star Charles Esten Shares Personal Experience in Battling R..
2014 INCYTE : Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial ..
2014 NOVARTIS : announces safety and efficacy benefit of Jakavi in global clinical tr..
2014 INCYTE : Secures FDA Approval for Jakafi (ruxolitinib)
2014 INCYTE : CURE Magazine and Incyte Honor MPN Heroes
2014 INCYTE : FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with U..
2014 INCYTE : Multiple Data Presentations at the 2014 American Society of Hematology ..
2014 INCYTE : Assigned Patent
2014 INCYTE : Patent Issued for Metabolites of the Janus Kinase Inhibitor ®-3-(4-(7H-..
2014 INCYTE : Bellicum Appoints Reid Huber, Ph.D. to Board of Directors
2014 INCYTE : CURE Magazine and Incyte to Honor MPN Heroes
2014 INCYTE : Assigned Patent
2014 INCYTE : Bellicum Appoints Reid Huber, Ph.D. to Board of Directors
2014 INCYTE : Bellicum Appoints Reid Huber, Ph.D. to Board of Directors
2014 INCYTE : to Present at Upcoming Investor Conferences
2014 INCYTE : Assigned Patent
2014 INCYTE : Reports 2014 Third-Quarter Financial Results and Updates Shareholders o..
2014 INCYTE : Posts 2014 3Q Financial Results
2014 INCYTE : Assigned Patent
2014 INCYTE : Assigned Patent
2014 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
2014 INCYTE : beats Street 3Q forecasts
2014 INCYTE : Results of Operations and Financial Condition, Financial Statements and..
2014 INCYTE : Reports 2014 Third-Quarter Financial Results and Updates Shareholders o..
2014 INCYTE : to Present at the Nomura BioPharma Conference
2014 INCYTE : to Present at the Nomura BioPharma Conference
2014 INCYTE : Change in Directors or Principal Officers, Financial Statements and Exh..
2014 INCYTE : Gets Payment Related to Reimbursement of Jakavi (ruxolitinib)
2014 INCYTE : Appoints David Gryska as Executive Vice President and Chief Financial O..
2014 INCYTE : to Report Third Quarter 2014 Financial Results on October 30
2014 INCYTE : Earns $60 Million Milestone Related to Reimbursement of Jakavi® ruxolit..
2014 INCYTE : Garners Payment Related to Reimbursement of Jakavi (ruxolitinib)
2014 INCYTE : Other Events, Financial Statements and Exhibits (form 8-K)
2014 INCYTE : Earns $60 Million Milestone Related to Reimbursement of Jakavi® (ruxoli..
2014 INCYTE : Assigned Patent
2014 INCYTE : Assigned Patent
2014 INCYTE : Patent Issued for Salts of the Janus Kinase Inhibitor ®-3-(4-(7H-Pyrrol..
2014 INCYTE : Join Incyte and Others to Raise Awareness of Rare Blood Cancers Called ..
2014 INCYTE : to Present at the 21st Annual BioCentury NewsMakers Conference
2014 INCYTE : Assigned Patent
2014 INCYTE : Patent Issued for Salts of the Janus Kinase Inhibitor ®-3-(4-(7H-Pyrrol..
2014 INCYTE : to Present at the 21st Annual BioCentury NewsMakers Conference
2014 INCYTE : Join Incyte and Others to Raise Awareness of Rare Blood Cancers Called ..
2014 TETRALOGIC PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Delaware (Sept..
2014 INCYTE : Assigned Patent
2014 INCYTE : Diagnostics lab makes yet another acquisition
2014 INCYTE : Market Movers - Biotech Stocks -- Progenics Pharma, Rexahn Pharma, Immu..
2014 INCYTE : Secures FDA sNDA for Jakafi (ruxolitinib)
2014 INCYTE : Gets FDA sNDA for Jakafi (ruxolitinib)
2014 INCYTE : Assigned Patent
2014 INCYTE : Announces Clinical Trial Agreement to Evaluate Combination of Two Novel..
2014 INCYTE : FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib)..
2014 Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders..
2014 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
1  2  3  4  5Next
Advertisement
Chart
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF